| Literature DB >> 25287789 |
Claudia Giavoli, Claudia Tagliabue, Eriselda Profka, Laura Senatore, Silvia Bergamaschi, Giulia Rodari, Anna Spada, Paolo Beck-Peccoz, Susanna Esposito1.
Abstract
BACKGROUND: A number of studies of adults have shown that pituitary deficiencies can develop in a considerable proportion of subjects during the acute phase of meningitis or years after the infection has disappeared. The results of the very few studies of the impact of pediatric meningitis on hypothalamic-pituitary function are conflicting.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25287789 PMCID: PMC4196011 DOI: 10.1186/1472-6823-14-80
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Growth parameters, and clinical and demographic characteristics of children with a previous diagnosis of acute meningitis
| Patient No. | Gender/age (years) | Height (SDS) | BMI (SDS) | Tanner stage | Etiology of meningitis | Time from acute event (months) |
|---|---|---|---|---|---|---|
|
| M/10.1 | -1.1 | -0.63 | 2 | Enterovirus | 3 |
|
| M/2.8 | 1.6 | 0.69 | 1 | Enterovirus | 33 |
|
| M/6.5 | 1.0 | -0.14 | 1 | Enterovirus | 15 |
|
| F/6.3 | 2.0 | 0.44 | 1 | Enterovirus | 15 |
|
| F/3.9 | 0.9 | 0.01 | 1 | Enterovirus | 16 |
|
| M/3.5 | 0.2 | 0.41 | 1 | Varicella zoster virus | 8 |
|
| M/6.9 | -0.7 | -0.45 | 1 | Varicella zoster virus | 12 |
|
| M/3.3 | 1.3 | 0.98 | 1 | Varicella zoster virus | 23 |
|
| M/13.9 | 0.4 | 0.65 | 3 |
| 32 |
|
| F/3.6 | 0.6 | 0.41 | 1 |
| 29 |
|
| M/6.3 | -0.4 | 0.00 | 1 |
| 11 |
|
| M/4.9 | 1.0 | -0.55 | 1 |
| 37 |
|
| F/8.9 | 0.8 | -1.42 | 1 |
| 13 |
|
| M/12.9 | 1.9 | 2.28 | 2 |
| 12 |
|
| F/1.5 | -0.4 | -0.51 | 3 |
| 15 |
|
| M/1.1 | 1.2 | -1.14 | 1 |
| 10 |
|
| M/1.1 | -1.1 | -1.58 | 1 | MRSA | 6 |
|
| M/3.2 | 2.0 | -1.58 | 1 |
| 32 |
|
| M/12 | 0.3 | -0.63 | 1 |
| 18 |
M = male; F = female; SDS = standard deviation scores; BMI = body mass index, MRSA: methicillin-resistant Staphylococcus aureus.
Main laboratory parameters
| Patient No. | IGF-I (SDS) | TSH mcIU/ml (n.v. 0.6-7.6) | FT4pg/mL (n.v. 8–17) | FT3 pg/mL (n.v. 2.5-5.3) | PRL ng/mL (n.v. 1.7-16) | Potassium mEq/L (n.v. 3.5-5.1) | Sodium mEq/L (n.v. 135–145) |
|---|---|---|---|---|---|---|---|
|
| -0.35 | 1.81 | 17.5 | 4.4 | 7.1 | 3.8 | 135 |
|
| -1.18 | 5.19 | 16.6 | 5.4 | 10.6 | 3.9 | 139 |
|
| -1.49 | 2.66 | 10.4 | 3.8 | 15.1 | 3.9 | 140 |
|
| -0.15 | 1.8 | 13.2 | 4 | 2.6 | 4.2 | 139 |
|
| -1.18 | 2.05 | 12.1 | 4.1 | 7.4 | 5 | 139 |
|
| -1.09 | 2.18 | 11.9 | 4.8 | 5.0 | 3.7 | 131 |
|
| -0.15 | 1.7 | 14 | 5.2 | 13.7 | 4.7 | 143 |
|
| -0.47 | 2.15 | 13.6 | 4.1 | 13.6 | 4.8 | 140 |
|
| -0.98 | 2.44 | 10.8 | 3.9 | 7.4 | 4.7 | 142 |
|
| -1.50 | 2.66 | 10.4 | 3.8 | 15.1 | 4.3 | 140 |
|
| -1.25 | 2.72 | 13 | 4.5 | 7.4 | 4.2 | 139 |
|
| -1.46 | 1.29 | 13.5 | 4.4 | 8.7 | 4.2 | 140 |
|
| -1.17 | 4.56 | 13.2 | 4.3 | 5 | 4.4 | 143 |
|
| -1.29 | 2.17 | 9.8 | 4.3 | 1.9 | 4.8 | 141 |
|
| -1.51 | 1.58 | 13.3 | 4.6 | 14.8 | 4.3 | 139 |
|
| -1.46 | 2 | 11.6 | 4.4 | 13.4 | 4.8 | 138 |
|
| -1.51 | 2.88 | 15.9 | 5.5 | 9.1 | 4.4 | 138 |
|
| -0.57 | 2.27 | 11.4 | 5.2 | 5.6 | 4.9 | 137 |
|
| -0.11 | 1.69 | 12.8 | 4.4 | 2.9 | 4.5 | 138 |
SDS = standard deviation scores; n.v. = normal values; IGF-I = insulin-like growth factor I; TSH = thyroid- stimulating hormone; FT4 = free T4; FT3 = free T3; PRL = prolactin.
Figure 1Serum cortisol levels during SDST (standard dose Synachten test) in each patient. Cut-off for normal peak: 20 μg/dL (dashed line).